Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Portugal

European Innovation Council · Running

BRIGHT Best-in-class canceR dIaGnostic cHip for patient sTratification.

Coordinator
Rubynanomed Lda, Portugal
Runs
1 August 2022 to 31 December 2025
Status
Running
EU funding
€2.5m
Total cost
€3.6m
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
190138134

What the project is doing

In the project's own words, from its summary on CORDIS.

Through advanced microengineering and nanotechnology, we have developed a proprietary microfluidic-based liquid biopsy device, the RUBYchip™ (PCT/EP2016/078406). This technology allows for the isolation of all types of CTCs, keeping them viable and enabling the analysis of their phenotypic, genetic and functional characteristics, enabling unprecedented frequent monitoring of cancer progression in a minimally invasive and cost-efficient way.

Our chip isolates 70% of the very scarce CTCs from a 7.5mL blood sample of a cancer patient in less than 3 h and without the need of sample pre‐processing. This dramatic improvement in the sensitivity compared to competition is enabled by a unique microfilter network embedded in a microfluidic device that separates the CTCs from the healthy cells based on their size and deformability. Furthermore, the RUBYchip enables automation reducing inter-laboratory and inter-user dependence and ensuring reproducible analysis of CTCs.

Topics

Who is involved

OrganisationCityCountryRole
Rubynanomed LdaBragaPortugalCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI